Significant therapeutic efficacy with combined radioimmunotherapy and cetuximab in preclinical models of colorectal cancer

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1239-1245

  Vassileva, Vessela ^a   Rajkumar, Vineeth ^a   Mazzantini, Mario ^a   Robson, Mathew ^a   Badar, Adam ^b   Sharma, Surinder ^a   Arstad, Erik ^c   Hochhauser, Daniel ^a   Lythgoe, Mark F ^b   Boxer, Geoffrey M ^a   Pedley, Rosmund Barbara ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti EGFR therapy; Colorectal cancer; Combination therapy; Radioimmunotherapy; Radiosensitization

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DNA; PROTEIN KINASE; A5B7 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LIVER METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TUMOR GROWTH; TUMOR LOCALIZATION; XENOGRAFT; ANIMAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG SCREENING; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA DAMAGE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938884798     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.157362     Document Type: Article

References (31)

1. Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153-1164.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Navarro-Teulon I, Lozza C, Pelegrin A, Vives E, Pouget JP. General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013;5:467-487.
4. Dearling JL, Pedley RB. Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol). 2007;19:457-469.
5. Pouget J-P, Navarro-Teulon I, Bardies M, et al. Clinical radioimmunotherapy: the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720-734.
6. Lane DM, Eagle KF, Begent RH, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994;70:521-525.
7. 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009;15:4484-4492.
8. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med. 1996;37:1504-1510.
9. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31-42.
10. Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21:8.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
12. Liccardi G, Hartley JA, Hochhauser D. Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 2014;20:3496-3506.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
15. Shin HK, Kim MS, Lee JK, et al. Combination effect of cetuximab with radiation in colorectal cancer cells. Tumori. 2010;96:713-720.
16. El Emir E, Qureshi U, Dearling JL, et al. Predicting response to radioimmuno-therapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007;67:11896-11905.
17. Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adeno-carcinoma. Tumour Biol. 2012;33:2019-2029.
18. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53:852-864.
19. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer. 2010;46:1997-2009.
20. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555-1577.
21. Rajendran S, Salwa S, Gao X, et al. Murine bioluminescent hepatic tumour model. J Vis Exp. 2010;1977.
22. Dearling JL, Flynn AA, Qureshi U, et al. Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. Nucl Med Biol. 2009;36:883-894.
23. Vassileva V, Moriyama EH, De Souza R, et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br J Cancer. 2008;99:2037-2043.
24. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 2008;7:630-637.
25. Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319-323.
26. Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen. 2014;19:817-821.
27. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812-1820.
28. Modest DP, Brodowicz T, Stintzing S, et al. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology. 2012;83:241-247.
29. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127-1135.
30. Casey JL, Napier MP, King DJ, et al. Tumour targeting of humanised cross-linked divalent-fab[prime] antibody fragments: a clinical phase I/II study. Br J Cancer. 2002;86:1401-1410.
31. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219-244.